Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

QIAN Yujun, QIN Chunxia, SUN Lili, DING Huamin, LI Tiejun. A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007
Citation: QIAN Yujun, QIN Chunxia, SUN Lili, DING Huamin, LI Tiejun. A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007

A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment

doi: 10.3969/j.issn.1006-0111.2019.01.007
  • Received Date: 2018-06-11
  • Rev Recd Date: 2018-09-25
  • Objective To establish a high-throughput in-vitro screening cell model for anti-atherosclerosis leading compounds. Methods Hypoxia response element (HRE) was cloned into a luciferase reporter vector, pGL3-Enhancer, to construct pGL3-HIF-1α-HRE. The THP-1 human monocyte cell line was infected with the pGL3-HIF-1α-HRE and a stable cell line, THP-1-HIF-1α-HRE, was screened. Results Real-time PCR assay showed that HIF-1α expression and luciferase activity in THP-1-HIF-1α-HRE cells was effectively upregulated by hypoxia. The increase of HIF-1α expression and luciferase activity induced by hypoxia was significantly inhibited by lovastatin or curcumin. Conclusion THP1-HIF-1α-HRE, an in-vitro cell model for high-throughput screening lead compounds for anti-atherosclerosis (AS) was successfully established.
  • [1] ROSS R. Atherosclerosis-an inflammatory disease[J].New Engl J Med, 1999, 340(2):115-126.
    [2] KALIORA A C, DEDOUSSIS G V Z, SCHMIDT H. Dietary antioxidants in preventing atherogenesis[J]. Atherosclerosis, 2006, 187(1):1-17.
    [3] LIM C S, KIRIAKIDIS S, SANDISON A, et al. Hypoxia-inducible factor pathway and diseases of the vascular wall[J]. J Vasc Surg, 2013, 58(1):219-230.
    [4] PARATHATH S, MICK S L, FEIG J E,et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism[J]. Circ Res, 2011, 109(10):1141-1152.
    [5] PARATHATH S, YANG Y, MICK S, et al. Hypoxia in murine atherosclerotic plaques and its adverse effects on macrophages[J]. Trends Cardiovasc Med, 2013, 23(3):80-84.
    [6] SCHOLZ C C, TAYLOR C T. Targeting the HIF pathway in inflammation and immunity[J]. Curr Opin Pharmacol, 2013, 13(4):646-653.
    [7] MAZI RE C, MAZI RE J C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein[J]. Free Radic Bio Med, 2009, 46(2):127-137.
    [8] RODR GUEZ J A, NESPEREIRA B, P REZ-ILZARBE M, et al. Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL[J].Cardiovasc Res, 2005,65(3):665-673.
    [9] ZHU X Y, RODRIGUEZ-PORCEL M, BENTLEY M D, et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia[J]. Circulation, 2004, 109(17):2109-2115.
    [10] SHATROV V A. Oxidized low-density lipoprotein (ox-LDL) triggers hypoxia-inducible factor-1α (HIF-1α) accumulation via redox-dependent mechanisms[J]. Blood, 2003,101(12):4847-4849.
    [11] JIANG G, LI T, QIU Y, et al. RNA interference for HIF-1α inhibits foam cells formation in vitro[J]. Eur J Pharmacol, 2007, 562(3):183-190.
    [12] MANOLESCU B, OPREA E, BUSU C, et al. Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway[J]. Biochimie, 2009, 91(11-12):1347-1358.
    [13] WILSON S H,HERRMANN J, LERMAN L O, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering[J]. Circulation, 2002,105(4):415-418.
    [14] DICHTL W. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2002, 23(1):58-63.
    [15] HOSSAIN C F, KIM Y P, BAERSON S R, et al. Saururus cernuus lignans-potent small molecule inhibitors of hypoxia-inducible factor-1[J]. Biochem Biophys Res Commun, 2005, 333(3):1026-1033.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(2674) PDF downloads(382) Cited by()

Related
Proportional views

A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment

doi: 10.3969/j.issn.1006-0111.2019.01.007

Abstract: Objective To establish a high-throughput in-vitro screening cell model for anti-atherosclerosis leading compounds. Methods Hypoxia response element (HRE) was cloned into a luciferase reporter vector, pGL3-Enhancer, to construct pGL3-HIF-1α-HRE. The THP-1 human monocyte cell line was infected with the pGL3-HIF-1α-HRE and a stable cell line, THP-1-HIF-1α-HRE, was screened. Results Real-time PCR assay showed that HIF-1α expression and luciferase activity in THP-1-HIF-1α-HRE cells was effectively upregulated by hypoxia. The increase of HIF-1α expression and luciferase activity induced by hypoxia was significantly inhibited by lovastatin or curcumin. Conclusion THP1-HIF-1α-HRE, an in-vitro cell model for high-throughput screening lead compounds for anti-atherosclerosis (AS) was successfully established.

QIAN Yujun, QIN Chunxia, SUN Lili, DING Huamin, LI Tiejun. A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007
Citation: QIAN Yujun, QIN Chunxia, SUN Lili, DING Huamin, LI Tiejun. A cell model for high-throughput screening lead compounds targeting HIF-1α for atherosclerosis treatment[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007
Reference (15)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return